[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610065":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":32,"studyPopulation":25,"armGroups":33,"interventions":43,"overallOfficials":62,"centralContacts":66,"locations":71,"responsibleParty":89,"collaborators":25,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":25,"eligibilityCriteria":96,"healthyVolunteers":93,"sex":97,"minAge":25,"maxAge":98,"enrollmentInfo":99,"targetDuration":25,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":25,"overallStatus":73,"whyStopped":25,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"St. Jude Children's Research Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":25},[9,13],{"measure":10,"description":11,"timeFrame":12},"Dose limiting toxicity (DLT) rate","Proportion of evaluable participants experiencing DLTs","up to 4 weeks after CAR T cell infusion",{"measure":14,"description":15,"timeFrame":12},"Incidence of adverse events (AEs)","AEs will be assessed and graded using CTCAE v5.0, except for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS), which will be graded according to ASTCT consensus guidelines. AEs will be summarized and reported descriptively",[17,21],{"measure":18,"description":19,"timeFrame":20},"Clinical antitumor activity","Best overall response after treatment as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and if applicable bone marrow evaluation","4-12 weeks after CAR T cell infusion",{"measure":22,"description":23,"timeFrame":24},"B7-H3-CAR T cell trafficking to tumor sites","Evaluate for the presence of B7-H3-CAR T cells in post-treatment tumor biopsies","2 weeks after CAR T cell infusion",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":25,"primaryPurpose":29,"observationalModel":25,"timePerspective":25,"maskingInfo":30},"NA","SINGLE_GROUP","TREATMENT",{"masking":31,"maskingDescription":25,"whoMasked":25},"NONE","This study is a phase I study designed to describe the safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy for the treatment of pediatric patients with B7-H3+ sarcoma.\n\nThe study will contain two-part eligibility criterion: one to proceed with autologous apheresis and manufacturing of CAR T cells, and a second to proceed with CAR T cell treatment.\n\nThe primary intervention is the administration of autologous B7-H3-CAR T cells, after priming with HFRT and administration of lymphodepleting chemotherapy. Peripheral blood mononuclear cells (PBMC) will be collected by autologous apheresis. Treatment will include HFRT to at least one site of disease, administered in parallel with a single course of lymphodepleting chemotherapy (fludarabine\u002Fcyclophosphamide) and followed by CAR T cell infusion. Participants are evaluated for a post-treatment tumor biopsy and may choose to be evaluated for a pre-treatment tumor biopsy. Participants who meet specified criteria will be eligible for optional additional treatment courses.",[34],{"label":35,"type":36,"description":37,"interventionNames":38},"RAD3CAR Treatment","EXPERIMENTAL","Peripheral blood mononuclear cells (PBMC) will be collected by autologous apheresis.\n\nTreatment will include HFRT to at least one site of disease, administered in parallel with a single course of lymphodepleting chemotherapy (fludarabine\u002Fcyclophosphamide) and followed by CAR T cell infusion.",[39,40,41,42],"Drug: Fludarabine","Drug: Cyclophosphamide","Drug: B7-H3-CAR T Cells","Radiation: Radiation Therapy",[44,49,53,57],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":25},"DRUG","Fludarabine","Intravenously on day -5, -4, -3 and -2",[35],{"type":45,"name":50,"description":51,"armGroupLabels":52,"otherNames":25},"Cyclophosphamide","Intravenously on day -3, -2",[35],{"type":45,"name":54,"description":55,"armGroupLabels":56,"otherNames":25},"B7-H3-CAR T Cells","Intravenously on day 0",[35],{"type":58,"name":59,"description":60,"armGroupLabels":61,"otherNames":25},"RADIATION","Radiation Therapy","5 or 8 treatment sessions (fractions), scheduled to complete on Day -2",[35],[63],{"name":64,"affiliation":5,"role":65},"Rebecca Epperly, MD","PRINCIPAL_INVESTIGATOR",[67],{"name":64,"role":68,"phone":69,"phoneExt":25,"email":70},"CONTACT","8662785833","referralinfo@stjude.org",[72],{"facility":5,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"RECRUITING","Memphis","Tennessee","38105","United States","US",{"type":80,"coordinates":81},"Point",[82,83],-90.04898,35.14953,{"lat":83,"lon":82},[86,88],{"name":64,"role":68,"phone":87,"phoneExt":25,"email":70},"866-278-5833",{"name":64,"role":65,"phone":25,"phoneExt":25,"email":25},{"type":90,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100610065","phase-1-hypofractionated-radiation-in-combination-with-b7-h3-car-t-cells-for-pediatric-patients-with-relapsedrefractory-sarcomas-100610065",false,"NCT07222735","Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed\u002FRefractory Sarcomas","INCLUSION CRITERIA\n\n\\*a previously collected, autologous leukapheresis product can be used for T cell production\n\nCollection and manufacturing eligibility\n\n* Age ≤ 21 years old\n* B7-H3+ sarcoma; B7-H3 expression will be evaluated by standard immunohistochemistry (IHC) using any previously obtained biopsy; a tumor is considered B7-H3 positive with a H score greater than or equal to 100\n\n  * Osteosarcoma\n  * Ewing Sarcoma\n  * Rhabdomyosarcoma Non-rhabdomyosarcoma soft tissue sarcomas\n* Evidence of relapsed (cancer that has completely responded \\[i.e., no evidence of disease using standard imaging modalities\\] to first-line therapy but has recurred for the first or subsequent time); or refractory (cancer that does not respond completely to treatment; cancer may be resistant at the beginning or may become resistant during treatment) disease after standard first-line therapy\n* Evaluable disease with presence of at least one lesion amenable to hypofractionated radiation therapy\n\n  * For dose expansion cohort: participants must also have additional evaluable disease beyond planned radiation field\n* Estimated life expectancy of \\> 12 weeks\n* Karnofsky or Lansky (age-dependent) performance score ≥ 60\n\n  * Participants with mobility limitations due to prior surgical intervention (i.e., amputation) but who are up in wheelchair or with other assistive devices will be considered ambulatory for the purpose of performance score determination\n* For females of child-bearing age:\n\n  * Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n  * Not lactating with intent to breastfeed\n* Participants must be eligible to undergo autologous apheresis or have an available previously collected autologous apheresis product\n\nTreatment eligibility\n\n* Age ≤ 21 years old at the time of manufacturing\n* B7-H3+ sarcoma\n* Evidence of relapsed or refractory disease after standard first-line therapy\n* Evaluable disease with the presence of at least one lesion amenable to hypofractionated radiation therapy\n\n  • For dose expansion cohort: participants must also have additional evaluable disease beyond the planned radiation field\n* Estimated life expectancy of \\> 8 weeks\n* Karnofsky or Lansky (age-dependent) performance score ≥ 60\n\n  • Participants with mobility limitations due to prior surgical intervention (i.e., amputation) but who are up in wheelchair or with other assistive device will be considered ambulatory for purpose of performance score determination.\n* Adequate cardiac function defined by echocardiogram with left ventricular ejection fraction ≥ 50%\n* Adequate renal function as defined by not exceeding the maximum serum creatinine listed below by age:\n\n  * 1 to \\\u003C2 years: 0.6\n  * 2 to \\\u003C6 years: 0.8\n  * 6 to \\\u003C10 years: 1\n  * 10 to \\\u003C13 years: 1.2\n  * 13 to \\\u003C16 years: male 1.5, female 1.4\n  * ≥ 16 years: male 1.7, female 1.4\n* Adequate pulmonary function defined as pulse oximetry ≥ 92% on room air\n* Total Bilirubin ≤3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age\n* Hemoglobin ≥ 7g\u002FdL (can be transfused)\n* Platelet count ≥ 50,000\u002FμL (can be transfused)\n* Absolute neutrophil count (ANC) ≥ 1000\u002FμL\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* For females of child-bearing age:\n\n  * Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n  * Not lactating with intent to breastfeed\n* If sexually active, agreement to use contraception until 3 months after T cell infusion\n\nEXCLUSION CRITERIA\n\nCollection and manufacturing eligibility\n\n* Known primary immunodeficiency\n* Known HIV positivity\n* Severe, uncontrolled intercurrent bacterial, viral, or fungal infection\n* Known active malignancy other than the B7-H3+ sarcoma being treated on study\n* Rapidly progressive disease (as assessed by the study PIs, with consideration for proximity to critical structures)\n* Presence of intracranial or spinal cord disease\n* Known underlying medical condition(s) for which, in the investigator's opinion, participation in this trial would not be in the best interest of the participant (e.g., compromises the health of the subject) or that could prevent, limit, or confound protocol assessments\n* Known severe hypersensitivity to corn starch or hydroxyethyl starch\n\nTreatment eligibility\n\n* Known primary immunodeficiency\n* Known HIV positivity\n* Severe, uncontrolled intercurrent bacterial, viral, or fungal infection\n* Known active malignancy other than the B7-H3+ sarcoma being treated on study\n* Receiving systemic steroid therapy exceeding the equivalent of 0.5 mg\u002Fkg\u002Fday of methylprednisolone, \\\u003C 7 days prior to CAR T cell infusion\n* Receiving systemic therapy \\\u003C 14 days prior to start of protocol therapy, which will interfere with the activity of the CAR product (in the opinion of the study PIs)\n* Received radiation therapy within the 4 weeks prior to start of protocol therapy\n* Rapidly progressive disease (as assessed by the study PIs, with consideration for proximity to critical structures)\n* Presence of intracranial or spinal cord disease\n* Known underlying medical condition(s) for which, in the investigator's opinion, participation in this trial would not be in the best interest of the participant (e.g., compromises the health of the subject) or that could prevent, limit, or confound protocol assessments\n* Known severe hypersensitivity to corn starch or hydroxyethyl starch","ALL","21 Years",{"count":100,"type":101},42,"ESTIMATED","INTERVENTIONAL",[104],"PHASE1","RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy.\n\nPrimary objective:\n\n\\- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation therapy (HFRT) and lymphodepleting chemotherapy in patients ≤ 21 years of age with relapsed\u002Frefractory B7-H3+ sarcomas.\n\nSecondary objectives:\n\n* To describe the antitumor activity of B7-H3-CAR T cells in combination with HFRT\n* To determine if B7-H3-CAR T cells traffic to tumor sites after combination treatment with HFRT",[107,108,109,110,111],"Sarcoma","Childhood Osteosarcoma","Childhood Rhabdomyosarcoma","Childhood Soft Tissue Sarcoma","Ewing Sarcoma","2026-02-06",{"date":114,"type":115},"2026-02-09","ACTUAL",{"date":117,"type":115},"2026-01-21",{"date":119,"type":101},"2031-11-05",{"name":5,"class":6},1]